The Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended that oral cladribine (Mavenclad) be reimbursed by provincial drug plans for the treatment of relapsing-remitting multiple sclerosis (RRMS). Patients who are eligible for oral cladribine are those with an inadequate response or poor tolerability with one prior disease-modifying therapy (DMT), and who have had at least one relapse within the previous 12 months.

QUICK POLL